Licenses genetic-medicine rights and provides research, development and manufacturing services to biopharmaceutical partners, while developing gene therapies for eye, salivary-gland and neurological conditions.
10-K for FY2025, filed Mar 30, 2026We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including…View ↗
On January 30, 2019, we and our wholly-owned subsidiary MeiraGTx UK II Limited entered into a Collaboration, Option and License Agreement…View ↗
MeiraGTx UK II Limited and Johnson & Johnson Innovative Medicine also entered into a Supply Agreement on the Closing Date pursuant to which…View ↗
At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or…View ↗
License partners pay for rights to genetic-medicine programs, including upfront and milestone payments; collaborators also pay for research, development and manufacturing services as work is performed.
10-K for FY2025, filed Mar 30, 2026On January 30, 2019, we and our wholly-owned subsidiary MeiraGTx UK II Limited entered into a Collaboration, Option and License Agreement…View ↗
Under the Asset Purchase Agreement, Johnson & Johnson Innovative Medicine paid us a non-refundable upfront cash purchase price of $65.0…View ↗
When the Company concludes that promises in a contract should be accounted for as a combined performance obligation and recognized over…View ↗
At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or…View ↗
10-K for FY2025, filed Mar 30, 2026
FY2025 revenue by product or service ↗$81.4M
10-K for FY2025, filed Mar 30, 2026
$81.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Service revenue - related party
Recurring
|
7.9% |
Service revenue - related party, FY2025
$6.4M Sources
|
Recurring |
|
License revenue
Licensed
10-K for FY2025, filed Mar 30, 2026 |
92% |
License revenue, FY2025
$75M Sources
|
Licensed |
Biopharmaceutical collaborators work directly with MeiraGTx on licenses and research, development and manufacturing; Johnson & Johnson also receives gene-therapy supply under a supply agreement.
10-K for FY2025, filed Mar 30, 2026On January 30, 2019, we and our wholly-owned subsidiary MeiraGTx UK II Limited entered into a Collaboration, Option and License Agreement…View ↗
MeiraGTx UK II Limited and Johnson & Johnson Innovative Medicine also entered into a Supply Agreement on the Closing Date pursuant to which…View ↗
At contract inception, the Company assesses the goods or services promised within the contract to determine whether each promised good or…View ↗
No. It lost $114.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$51.2MView ↗
8-K, filed Apr 24, 2026
On April 20, 2026 (the “Initial Closing Date”), MeiraGTx Holdings plc (the “Company”) and certain of its affiliates completed the initial…View ↗
8-K, filed Apr 16, 2026
On April 15, 2026 (the “Closing Date”), MeiraGTx Holdings plc (the “Company”) and its wholly-owned subsidiary MeiraGTx Ocular UK Limited, a…View ↗
Growing. Revenue grew 2.2x in 4 years, from $37.7M in FY2021 to $81.4M in FY2025, about 21% a year.
Competes with Spark Therapeutics, Voyager Therapeutics, and Lilly
10-K for FY2025, filed Mar 30, 2026There are other organizations working to improve existing therapies or to develop new therapies for our initially selected disease…View ↗
Loading...